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Abstract
Background: Maternal obesity is accompanied by maternal and fetal complications during and after pregnancy.
The risks seem to increase with degree of obesity. Leptin has been suggested to play a role in the development of
obesity related complications. Whether maternal leptin levels differ between obese and morbidly obese women,
during and after pregnancy, have to our knowledge not been previously described. Neither has the association
between maternal leptin levels and gestational weight gain in obese women. The aim was to evaluate if maternal
plasma leptin levels were associated with different degrees of maternal obesity and gestational weight gain.
Methods: Prospective cohort study including women categorized as obesity class I-III (n = 343) and divided into
three gestational weight gain groups (n = 304). Maternal plasma leptin was measured at gestational week 15, 29
and 10 weeks postpartum. Maternal Body Mass Index (BMI) was calculated from early pregnancy weight. Gestational
weight gain was calculated using maternal weight in delivery week minus early pregnancy weight. The mean value
and confidence interval of plasma-leptin were analysed with a two-way ANOVA model. Interaction effect between
BMI and gestational weight gain group was tested with a two-way ANOVA model.
Results: The mean maternal leptin concentrations were significantly higher in women with obesity class III compared to
women in obesity class I, at all times when plasma leptin were measured. The mean leptin concentrations were also
significantly higher in women with obesity class II compared to women in obesity class I, except in gestational week 29.
There was no difference in mean levels of plasma leptin between the gestational weight gain groups. No significant
interaction between BMI and gestational weight gain group was found.
Conclusions: Plasma leptin levels during and after pregnancy were associated with obesity class but not with degree of
gestational weight gain. These results are in concordance with epidemiological findings where the risk of obstetric
complications increases with increased maternal obesity class. The effect on obstetric outcome by degree of gestational
weight gain is less pronounced than the adverse effects associated with maternal obesity.
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Background
Maternal obesity is accompanied by several complications
for both mother and infant during and after pregnancy
[1, 2]. Maternal risks are gestational diabetes mellitus
(GDM), pre-eclampsia (PE), hypertension, increased dur-
ation of labour, caesarean delivery, postpartum haemor-
rhage etc. [1, 3–7]. Fetal risks include neural tube and heart
defects, macrosomia, stillbirth etc. [1, 3, 8]. The risks for a
majority of obesity related complications during pregnancy,
for both mother and infant, seem to increase with increas-
ing degree of obesity [1, 3, 8]. A pronounced gestational
weight gain (GWG) influences pregnancy outcome as well,
but to a lesser extent than maternal obesity [3, 9].
The pathogenetic mechanisms of obesity on obstetric
outcome have not yet been clarified. Obesity induces
inflammatory processes, associated with some pregnancy
outcomes like PE, gestational hypertension and GDM
[10, 11]. Leptin, secreted by adipose tissue, is one of
several adipokines. It is believed to act as a pro-inflam-
matory cytokine that might have a role in development of
obesity related complications [12–14]. Serum leptin con-
centrations correlate with body mass index (BMI) and per-
centage of body fat in humans [15, 16]. During
pregnancy, leptin is also produced by the placenta and
plays an important role for normal fetal development
and growth [12, 13, 17, 18]. High serum leptin levels seem
to be associated with adverse pregnancy outcomes, such
as PE, GDM and macrosomia [12, 17, 19, 20].
Prior studies have indicated an association between
leptin, body fat mass or maternal BMI, during pregnancy
[21–23]. Misra et al. demonstrated that leptin concentra-
tions in overweight/obese women were higher but in-
creased at a significantly lower rate across gestation
compared to normal-weight women [24]. A similar leptin
pattern across gestation, which differed according to pre-
pregnancy maternal BMI, was observed in a smaller
Brazilian cohort [25]. These studies mainly focused on the
longitudinal trends in maternal leptin levels during preg-
nancy and included few obese and morbidly obese women
[22, 24–26]. Hendler et al. demonstrated that maternal
leptin levels in the third trimester, increased with pre-
pregnancy BMI in 20 obese women [19]. Walsh et al.
compared leptin levels in a cohort of women subdivided
into those who exceeded the American Institute of
Medicine’s (IOM) GWG guidelines and those with rec-
ommended GWG. They found no difference in leptin
levels in early pregnancy but maternal leptin concentra-
tion in gestational week 28 were higher in women who
exceeded the GWG recommendation [27].
Whether maternal plasma leptin levels differ substan-
tially between obese and morbidly obese women, during
and after pregnancy, have to our knowledge not been
previously described. There are no available data on the
association between maternal leptin levels in obese women,
during and after pregnancy, and recommended GWG,
based on the IOM guidelines [28]. Accordingly, the aim of
the present study was to estimate whether maternal plasma
leptin levels were associated with different degrees of
maternal obesity (obesity class I-III) during and after
pregnancy and further to evaluate maternal plasma lep-
tin levels during and after pregnancy in obese women
with different levels of GWG, based on IOM guidelines.
Methods
Data were collected as part of a prospective cohort study
on obese pregnant women [29]. Between November 2003
and December 2005, all obese pregnant women (n = 754),
consecutively registered in early pregnancy in three ante-
natal clinics in Sweden, were approached to the study [29].
The inclusion criteria were early pregnancy BMI ≥ 30 and
knowledge of the Swedish language. The exclusion criteria
were pre-pregnant diagnosis of diabetes mellitus, thyroid
dysfunction or psychiatric disease treated with neuroleptic
drugs. A flow chart of the study is presented in Fig. 1. Out
of the 615 women who were eligible and invited to partici-
pate, 368 women were included in the study and 348 com-
pleted the study. Additionally five women, who expected
twins, were excluded, leaving 343 women with singleton
pregnancies as the present study population.
The study-population was categorized in three obesity
classes of early pregnancy BMI, based on the WHO defin-
ition; class I obesity = BMI 30–34.9, class II obesity = BMI
35–39.9 (morbid obesity) and class III obesity = BMI ≥ 40
(morbid obesity) [30]. BMI was defined as body weight in
kilograms divided by height in meter squared (kg/m2). All
women had their weight and height recorded in the gesta-
tion week eight to ten, which enabled calculation of BMI.
The study-population was also divided into three
groups of GWG: < 5 kg, 5–9 kg and > 9 kg. In 2009 the
IOM published guidelines advising optimal weight gain
during pregnancy, based on pre-pregnancy BMI. Ac-
cording to these guidelines, the recommended GWG
for obese women is 5–9 kg [28]. To calculate GWG we
used maternal weight in delivery week minus early preg-
nancy weight. If maternal weight in delivery week was miss-
ing, the weight 1 or 2 weeks before delivery, was used. A
total number of 304 women had information on GWG.
Gestational age was calculated based on fetal biometry at
the first trimester ultrasound. Data on maternal characteris-
tics and pregnancy complications were retrieved from com-
puterized patient records.
Maternal plasma leptin levels were measured in week
15 and 29 of gestation and 10 weeks postpartum. The
women fasted prior to sampling of maternal blood. Mater-
nal blood was collected in the morning in all patients.
For leptin analyses blood was collected in a test tube
with a clot activator and gel for serum separation. One
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hour after sampling, the blood was centrifuged, aliquoted
and serum was stored at −70° Celsius until analyses.
The maternal plasma leptin concentration was mea-
sured using a direct sandwich based ELISA (Millipore,
Billerica, USA). Human leptin was captured by a poly-
clonal antibody on a 96-well microtiter plate and unbound
material washed away. A secondary monoclonal biotinyl-
ated antibody was added to the captured human leptin
complex followed by streptavidin-horseradish peroxidase.
The enzyme activity was measured spectrophotometrically
(Victor 3, PerkinElmer, Waltham, MA, USA) at 450 nm
after a last step of acidification of the sample products.
Increased absorbance was directly proportional to the
amount of captured human leptin in unknown samples
derived from a generated standard-curve. In a sample size
of 25 μL, the limit of sensitivity of the assay was
0.2 ng +/− 2 SD. The within and between assay vari-
ation was 4.6 and 6.2 % respectively. The specificity of
the assay was 100 % for human leptin. No cross-reactivity
was found for human pro-insulin, insulin, insulin-growth
factor I and II or Glucagon.
Differences in categorical demographic variables as
well as obstetric outcomes, between maternal obesity
class I-III, were analysed using Pearson’s Chi-square test
Fig. 1 Flow-chart of the cohort
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and ANOVA was used for analysing differences in con-
tinuous variables and outcomes (maternal age, birth weight,
GWG and gestational length in weeks.) Categorical vari-
ables and outcomes were expressed as numbers (percent-
age) and if continuous as mean (SD).
The mean value and confidence interval of plasma-
leptin during and after pregnancy in women with obesity
class I-III and in obese women in three different GWG
groups were analysed with a two-way ANOVA model.
(Bonferroni adjusted within each gestational week).
Interaction effect between Maternal BMI and GWG
was tested with a two-way ANOVA model.
General linear models were used to test possible con-
founding in addition to the main effect model of BMI and
gestational weight gain.
All analyses were performed using IBM SPSS version
23 (IBM Inc, Armonk, NY). A p-value <0.05 was consid-
ered statistically significant.
The Regional Ethical Review Board in Linköping,
Sweden approved this study (No 03–231).
Results
Out of the 343 women included in the study, 223
(65.0 %) were classified as obesity class I, 77 (22.4 %)
were defined as obesity class II and 43 (12.5 %) as obes-
ity class III. Of these 343 women, 304 (88.6 %) women
had information that enabled calculation of gestational
weight gain. A total number of 50 (16.4 %) women gained
less than 5 kg (low GWG), 87 (28.6 %) gained 5–9 kg (rec-
ommended GWG) and 167 (54.9 %) exceeded the IOM
gestational weight gain guidelines, i.e. more than 9 kg.
Maternal demographic characteristics, pregnancy out-
come and complications over the BMI strata are presented
in Tables 1 and 2. No differences in mean maternal age,
parity, mean gestational age, birth weight, smoking and
alcohol usage in first trimester were found between the
groups. Mean GWG, was significant lower in obesity class
III compared to obesity class I and class II. The distribu-
tion of GDM and hypertension before pregnancy did not
differ substantially between the obesity classes. The preva-
lence of PE increased with increasing BMI.
In gestational week 15, samples from 340 (99.1 %)
women were available for measurement of leptin levels
and in gestational week 29, 331 (96.5 %) women. At
10 weeks post partum, leptin levels were measured in 295
(86.0 %) women (Fig. 1).
The median week, 25th and 75th percentiles and the
lowest and highest value of pregnancy week or week
postpartum when blood was drawn for leptin analyses,
are presented in Table 3. There was no significant correl-
ation between gestational week, when blood was drawn
for leptin analyses, and the value of leptin, within each
time-period of leptin measurement (week 15 p = 0.33,
week 29 p = 0.45 and 10 weeks postpartum p = 0.70). Since
there was no significant correlation between gestational
week at leptin analyses and the value of leptin, within each
time-period of leptin measurement, the leptin analyses
have not been adjusted for gestational week at time of
leptin measurement.
No significant interaction was found between maternal
BMI and GWG, therefore the analyses on leptin and
GWG-group were not adjusted for BMI and vice versa.
The mean maternal plasma leptin concentrations and
95 % confidence interval in the three obesity classes are
presented in Fig. 2. Mean maternal leptin concentrations
during and after pregnancy seem to be associated with
degree of maternal obesity. The mean maternal leptin
concentrations were significantly higher in women with
obesity class III compared to women in obesity class I,
at all times when plasma leptin were measured. The mean
leptin concentrations were also significantly higher in
women with obesity class II compared to women in obes-
ity class I, except in gestational week 29. Postpartum the
mean leptin concentrations were higher with increasing
obesity category, although not reaching statistically signifi-
cant difference between women in obesity class II and III.
The mean maternal plasma leptin concentrations
and 95 % confidence interval, in the GWG groups are
presented in Fig. 3. Mean maternal leptin concentra-
tions during and after pregnancy do not seem to be as-
sociated with degree of GWG. There was no significant
difference in plasma-leptin levels during and after preg-
nancy in obese women classified according to degree of
Table 1 Maternal characteristics and pregnancy outcome in relation to maternal obesity class. Continuous variables Mean (Std)
Obesity class I Obesity class II Obesity class III P-value
N = 223 N = 77 N = 43
Maternal age (years) 30.0 (4.7) 30.4 (4.4) 29.0 (5.3) 0.322
Gestational length (full weeks) 39.2 (2.0) 39.8 (1.4) 39.0 (2.6) 0.076
Birth-weight (gram) 3708 (594) 3713 (448) 3670 (811) 0.920
Weight gain during pregnancy (kg) 10.6 (5.6) 9.6 (6.0) 7.7 (6.1) 0.015
N = 203 N = 66 N = 35
P < 0.05 statistical significance in difference between obesity class I-III groups
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GWG, with one exception. Obese women with > 9 kg
GWG had significantly higher mean plasma leptin con-
centration in pregnancy week 29 compared to obese
women with recommended GWG (5–9 kg).
No significant confounding was found using general
linear models. The resulting model included only the
main effects of BMI and GWG (data not shown).
Discussion
This large study included 223 women in obesity class I
and 120 women with morbid obesity (obesity class II
and III) and showed higher leptin levels during and after
pregnancy in women with morbid obesity, compared to
women in obesity class I. Thus, at each leptin measure-
ment during and after pregnancy maternal leptin levels
were significantly higher among women in obesity class
III compared to obesity class I women. There was no
significant difference in maternal leptin levels at 15 weeks
gestation and postpartum between low, recommended
and excessive GWG. At 29 weeks gestation measurement
women with excessive weight gain had a significantly higher
leptin levels than women in obesity class II.
It is well described in epidemiological studies that the
risk-estimates of adverse obstetric and neonatal outcome
vary substantially between obesity class I and obesity class
III [8, 31]. Leptin and other adipokines have been studied
in relation to different adverse outcomes as well and have
been found to be elevated in complicated pregnancies
Table 2 Maternal characteristics and pregnancy outcome in relation to maternal obesity class. Categorical variables N (%)
Obesity class I Obesity class II Obesity class III P-value
Parity 0.714
Nulliparous 96 (43.0) 36 (46.8) 21 (48.8)
Multiparous 127 (57.0) 41 (53.2) 22 (51.2)
Smoking in pregnancy 0.059
No 206 (93.2) 72 (94.7) 35 (83.3)
Yes 15 (6.8) 4 (5.3) 7 (16.7)
Alcohol in first trimester #
No/rarely 223 (100.0) 77 (100.0) 43 (100.0)
Yes 0 (0.0) 0 (0.0) 0 (0.0)
Pre-term (<37 weeks) 0.046
No 209 (94.6) 76 (100.0) 38 (90.5)
Yes 12 (5.4) 0 (0.0) 4 (9.5)
Post-term (≥42 weeks) 0.993
No 206 (93.2) 71 (93.4) 39 (92.9)
Yes 15 (6.8) 5 (6.6) 3 (7.1)
GDM 0.505
No 211 (94.6) 75 (97.4) 40 (93.0)
Yes 12 (5.4) 2 (2.6) 3 (7.0)
Pre-eclampsia 0.009
No 211 (94.6) 68 (88.3) 35 (81.4)
Yes 12 (5.4) 9 (11.7) 8 (18.6)
Hypertension pre-pregnancy #
No 221 (99.1) 77 (100.0) 42 (97.7)
Yes 2 (0.9) 0 (0.0) 1 (2.3)
GDM = Gestational diabetes mellitus
P < 0.05 statistical significance in difference between obesity class I-III groups
# = Assumption for chi2-test not fulfilled











N = 340 N = 331 N = 295
Min 10 24 6
25 percentile 14 28 9
Median 15 29 10
75 percentile 16 30 12
Max 22 33 28
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[12, 17, 19, 20]. Increased leptin levels have been found
in women with PE [19, 20]. If such proteins are in-
volved in the well described step-wise increased risk of
adverse outcomes for both the mother and the infant
for each higher obesity class, the levels of the adipo-
kines should vary substantially with the degree of obes-
ity. Results in this study add knowledge on this issue by
showing a significant difference in leptin levels between
the three degrees of obesity.
There are some previous studies indicating that maternal
leptin levels are associated with maternal pre-pregnancy
BMI [19, 22, 24–26]. Misra et al. studied the longitudinal
effects of maternal pre-pregnancy BMI on serum leptin
concentrations during pregnancy in 143 women, catego-
rized as non-overweight or overweight/obese. Leptin levels
were analysed five times during pregnancy. Leptin concen-
trations were higher in the overweight/obese group but
increased at a significantly lower rate across gestation, com-
pared to normal weight [24]. Similar results were presented
in Brazilian study including 42 women, categorized as
normal-weight or overweight/obese, according to their
pre-pregnancy BMI [25] Yang et al. reported that serum
leptin concentrations in 114 women, with a normal
singleton pregnancy, correlated with gestational age,
maternal bodyweight and BMI in the three trimesters
of pregnancy [22]. This is in accordance with findings
in the present study. However there are differences. The
majority of previous studies were based on relatively small
cohorts and often analysed obese and overweight women
as one group or with few obese individuals included.
This study showed that there was no difference in
maternal plasma leptin levels during and after preg-
nancy in obese women with excessive GWG, compared
to obese women with recommended GWG, with one
exception. Among women with excessive weight gain in
gestational week 29, women in obesity class III had
significantly higher leptin levels compared to those in
obesity class II. Although the confidence limits are close
to each other but not overlapping. It is possible that exces-
sive weight gain in late second trimester contributes to
significantly higher leptin levels. It seemed though that the
degree of weight gain during pregnancy in obese women
is of minor importance for the actual serum leptin value
during and after pregnancy compared to early pregnancy
BMI. Walsh et al. prospectively studied serum leptin con-
centration in 621 pregnant women, subdivided into those
Fig. 2 Plasma leptin values during and after pregnancy in women with obesity class I-III (in figure class 1–3). Leptin values are mean and 95 % confidence
interval (Bonferroni adjusted within each gestational week). Non-overlapping confidence interval implies significant differences (p< 0.05)
Fig. 3 Plasma leptin values during and after pregnancy in obese women divided in low, recommended and excessive gestational weight gain
groups. Leptin values are mean and 95 % confidence interval (Bonferroni adjusted within each gestational week). Non-overlapping confidence
interval implies significant differences (p < 0.05)
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who did (n = 267) and those who did not (n = 354) exceed
the IOM gestational weight gain guidelines, regardless of
BMI in early pregnancy. Maternal plasma leptin concen-
trations were measured in early pregnancy and in gesta-
tional week 28. The leptin levels were significantly higher
in women with excessive weight gain in gestational week
28 but not in early pregnancy [27].
Excessive GWG has previously been shown to increase
risk factors related to obstetric and neonatal outcome in
obese women [9], although to a lower magnitude than
risks associated with morbidly obesity. Epidemiological
data have shown that the most favourable obstetric and
neonatal outcome among obese women is related to low
GWG, except for birth of small for gestational age in-
fants [32, 33].
This study has certain strengths and limitations. One
of the strength is the large number of obese individuals
included, which enabled analyses of three subgroups of
obesity. In addition, BMI was based on measured weight
in week eight to ten of gestation. The IOM guidelines
are based on pre-pregnancy weight. However during the
first two months of pregnancy, the weight gain is min-
imal [34]. Further, information on GWG was available in
a majority of the obese women included, which enabled
a division into three groups according to degree of GWG.
A thorough baseline evaluation on maternal comorbidity
and demographic variables and continuous registration of
maternal complications in all study subjects were also
available. This information made it possible to demon-
strate that there were no major differences between the
different obesity classes concerning variables that could
have influenced the maternal leptin levels.
There are limitations of this study. The postpartum
measurement of leptin could only be performed in 86 %
of the study subjects since not all women attended the
proposed postpartum control. Apart from this, almost
all study subjects (98.5 %) had complete information on
leptin concentration during pregnancy. It must also be
kept in mind when interpreting the data, that although a
large sample size in the study-population, numbers in
certain subgroups were low. Another limitation is the
lack of data on maternal leptin at time of delivery.
Conclusions
In conclusion, this study demonstrated that maternal
plasma leptin levels during and after pregnancy differed
significantly between the women with obesity and mor-
bid obesity. Further no major differences in leptin levels
were defined between women with low, recommended
and excessive GWG. That is in concordance with obser-
vations done in epidemiological studies where the most
severe complications during and after pregnancy occur
among morbidly obese women and the amount of GWG
could alter these risks marginally.
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